Illumina (ILMN)
(Delayed Data from NSDQ)
$131.20 USD
-3.19 (-2.37%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $131.08 -0.12 (-0.09%) 7:58 PM ET
1-Strong Buy of 5 1
D Value C Growth F Momentum D VGM
Company Summary
San Diego, CA.-based Illumina Inc. is a life sciences company, which provides tools and integrated systems for analysis of genetic variation and function. Using its proprietary technologies, the company provides innovative sequencing- and array-based solutions for genotyping, copy number variation analysis, methylation studies, and gene expression profiling of DNA and RNA. Its customers include leading genomic research centers, academic institutions, government laboratories, hospitals and reference laboratories as well as pharmaceutical, biotechnology, agrigenomics, commercial molecular diagnostic and consumer genomics companies.
Illumina generates revenue from two segments:
Product revenues (84% of total revenues ...
Company Summary
San Diego, CA.-based Illumina Inc. is a life sciences company, which provides tools and integrated systems for analysis of genetic variation and function. Using its proprietary technologies, the company provides innovative sequencing- and array-based solutions for genotyping, copy number variation analysis, methylation studies, and gene expression profiling of DNA and RNA. Its customers include leading genomic research centers, academic institutions, government laboratories, hospitals and reference laboratories as well as pharmaceutical, biotechnology, agrigenomics, commercial molecular diagnostic and consumer genomics companies.
Illumina generates revenue from two segments:
Product revenues (84% of total revenues in 2023, down 4.2% from 2022) consist of sales proceeds from the consumables and instruments used in genetic analysis.
Service and other revenue (16%, up 13.6%) primarily consists of revenue generated from genotyping and sequencing services, instrument service contracts, development and licensing agreements, and cancer detection testing services related to the GRAIL business.
Next-Generation Sequencing (NGS)
Illumina’s portfolio of sequencing platforms represents a family of systems that are designed to meet the workflow, output, and accuracy demands of a full range of sequencing applications. The company’s MiSeq sequencing system is a low-cost desktop sequencing system that provides individual researchers with rapid turnaround time, high accuracy and streamlined workflow. NextSeq 500, launched in January 2014, provides flexibility from whole genome sequencing to targeted panels in a desktop platform. The HiSeq 2500 sequencing system allows customers to sequence an entire human genome in approximately a day.
In 2022, Illumina announced its new production-scale sequencing systems, NovaSeq X Series (NovaSeq X and NovaSeq X Plus), which can sequence a human genome for as little as $200.
Following the acquisition of GRAIL in 2021, from Jan 1, 2023, the company reports through two segments — Core lllumina (relates to the core operations) and GRAIL. In 2023, Core Illumina comprised 98.5% of the company’s consolidated revenues, while GRAIL service and other revenue comprised the rest 1.5%.
General Information
Illumina, Inc
5200 ILLUMINA WAY
SAN DIEGO, CA 92122
Phone: 858-202-4500
Fax: 858-202-4766
Email: ir@illumina.com
Industry | Medical - Biomedical and Genetics |
Sector | Medical |
Fiscal Year End | December |
Last Reported Quarter | 6/30/2024 |
Exp Earnings Date | 11/14/2024 |
EPS Information
Current Quarter EPS Consensus Estimate | 0.87 |
Current Year EPS Consensus Estimate | 3.63 |
Estimated Long-Term EPS Growth Rate | NA |
Exp Earnings Date | 11/14/2024 |
Price and Volume Information
Zacks Rank | |
Yesterday's Close | 134.39 |
52 Week High | 145.50 |
52 Week Low | 87.39 |
Beta | 1.15 |
20 Day Moving Average | 1,394,180.88 |
Target Price Consensus | 149.78 |
4 Week | -0.14 |
12 Week | 25.69 |
YTD | -5.77 |
4 Week | -1.33 |
12 Week | 20.36 |
YTD | -21.19 |
Shares Outstanding (millions) | 159.30 |
Market Capitalization (millions) | 20,900.16 |
Short Ratio | NA |
Last Split Date | 9/23/2008 |
Dividend Yield | 0.00% |
Annual Dividend | $0.00 |
Payout Ratio | 0.00 |
Change in Payout Ratio | 0.00 |
Last Dividend Payout / Amount | 6/25/2024 / $3.11 |
Fundamental Ratios
P/E (F1) | 36.19 |
Trailing 12 Months | 142.61 |
PEG Ratio | NA |
vs. Previous Year | 12.50% |
vs. Previous Quarter | 300.00% |
vs. Previous Year | -5.44% |
vs. Previous Quarter | 3.35% |
Price/Book | 14.55 |
Price/Cash Flow | 36.62 |
Price / Sales | 4.72 |
6/30/24 | 3.08 |
3/31/24 | 2.31 |
12/31/23 | 2.20 |
6/30/24 | 1.60 |
3/31/24 | 1.31 |
12/31/23 | 1.25 |
6/30/24 | 1.11 |
3/31/24 | 1.75 |
12/31/23 | 1.66 |
6/30/24 | 0.86 |
3/31/24 | 1.36 |
12/31/23 | 1.29 |
6/30/24 | 3.27 |
3/31/24 | 3.07 |
12/31/23 | 3.04 |
6/30/24 | -68.73 |
3/31/24 | -28.71 |
12/31/23 | -25.78 |
6/30/24 | -68.53 |
3/31/24 | -25.55 |
12/31/23 | -24.80 |
6/30/24 | 9.01 |
3/31/24 | 35.99 |
12/31/23 | 36.18 |
6/30/24 | 2.87 |
3/31/24 | 2.89 |
12/31/23 | 2.93 |
6/30/24 | 1.04 |
3/31/24 | 0.26 |
12/31/23 | 0.26 |
6/30/24 | 50.92 |
3/31/24 | 20.63 |
12/31/23 | 20.58 |